U.S. STOCKS ON THE MOVE-Triton, TESSCO, Creative Medical
Brief: ESSA Pharma Announces Clinical Trial Support Agreement With Janssen To Evaluate EPI-7386 Combinations In Patients With Prostate Cancer
ESSA Pharma rises on collaboration with Johnson & Johnson
Essa Pharma Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Essa Pharma Reports Financial Results For Q1 2022
Essa Pharma Inc Expected To Post A Loss Of 23 Cents A Share: Earnings Preview
Brief: ESSA Pharma Provides Corporate Update, Reports Q4 Net Loss Of $6.3 Mln
Essa Pharma Inc Reports Results For The Quarter Ended In September: Earnings Summary
Essa Pharma Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Insperity, Nikola, First Solar
U.S. STOCKS ON THE MOVE-Natgas, Wynn Resorts, Ascendis Pharma
U.S. STOCKS ON THE MOVE-Terran Orbital, SunCoke Energy, Alzamend Neuro
ESSA Pharma down as partner stops enrollment in prostate cancer study
Brief: Essa Provides An Update On Its Clinical Collaboration With Janssen
Brief: Avidity Partners Management LP Reports 8.5% Passive Stake In Essa Pharma Inc
Brief: Essa Pharma Inc - Epi-8207 Shows Robust Potency Degrading Ar, Including Ar Splice Variants And Clinically Relevant Ar Mutants
Epix Pharmaceuticals surges on positive cancer trial data
Brief: Updated Results From The Phase 1/2 Study Of Essa's Lead Candidate Epi-7386 In Combination With Enzalutamide Highlighted At The 29Th Annual Prostate Cancer Foundation Scientific Retreat
Brief: ESSA Pharma Appoints Philip Kantoff To Its Board Of Directors